@article {44703,
	title = {Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome},
	journal = {Molecular Therapy Nucleic Acids},
	volume = {30},
	year = {2022},
	note = {Pilala, Katerina-MarinaPapadimitriou, Maria-AlexandraPanoutsopoulou, KonstantinaBarbarigos, PetrosLevis, PanagiotisKotronopoulos, GeorgiosStravodimos, KonstantinosScorilas, AndreasAvgeris, Margaritiseng2022/11/03 06:00Mol Ther Nucleic Acids. 2022 Oct 7;30:311-322. doi: 10.1016/j.omtn.2022.10.001. eCollection 2022 Dec 13.},
	month = {Dec 13},
	pages = {311-322},
	abstract = {Owing to its highly heterogeneous molecular landscape, bladder cancer (BlCa) is still characterized by non-personalized treatment and lifelong surveillance. Motivated by our previous findings on miR-143/145 value in disease prognosis, we have studied the underlying epigenetic regulation of the miR-143/145 cluster in BlCa. Expression and DNA methylation of miR-143/145 cluster were analyzed in our screening (n = 162) and The Cancer Genome Atlas Urothelial Bladder Carcinoma (TCGA-BLCA; n = 412) cohorts. Survival analysis was performed using tumor relapse and progression as clinical endpoints for non-muscle-invasive bladder cancer (NMIBC; TaT1), while disease progression and patients{\textquoteright} death were used for muscle-invasive bladder cancer (MIBC; T2-T4). TCGA-BLCA served as validation cohort. Bootstrap analysis was carried out for internal validation, while decision curve analysis was used to evaluate clinical benefit. TCGA-BLCA and screening cohorts highlighted MIR145 core promoter as the pivotal, epigenetic regulatory region on cluster{\textquoteright}s expression. Lower methylation of MIR145 core promoter was associated with aggressive disease phenotype, higher risk for NMIBC short-term progression, and poor MIBC survival. MIR145 methylation-fitted multivariate models with established disease markers clearly enhanced patients{\textquoteright} risk stratification and prediction of treatment outcome. MIR145 core promoter methylation was identified as a potent epigenetic regulator of miR-143/145 cluster, supporting modern personalized risk stratification and management in BlCa.},
	keywords = {bladder tumors, DNA Methylation, epigenetics, miRNA, MT: Non-coding RNAs, Prognosis, pyrosequencing, tumor progression, urothelial bladder carcinoma},
	isbn = {2162-2531 (Print)2162-2531 (Electronic)2162-2531 (Linking)},
	author = {Pilala, K. M. and Papadimitriou, M. A. and Panoutsopoulou, K. and Barbarigos, P and Levis, P. and Kotronopoulos, G. and Stravodimos, K. and Scorilas, A. and Avgeris, M.}
}
